DE69615017D1 - Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung - Google Patents

Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung

Info

Publication number
DE69615017D1
DE69615017D1 DE69615017T DE69615017T DE69615017D1 DE 69615017 D1 DE69615017 D1 DE 69615017D1 DE 69615017 T DE69615017 T DE 69615017T DE 69615017 T DE69615017 T DE 69615017T DE 69615017 D1 DE69615017 D1 DE 69615017D1
Authority
DE
Germany
Prior art keywords
active ingredient
phase
amorphous
pharmaceutical form
pct
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69615017T
Other languages
English (en)
Inventor
Janez Kerc
Barbara Rebic
Bojan Kofler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lek Pharmaceuticals dd
Original Assignee
Lek Pharmaceuticals and Chemical Co dd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lek Pharmaceuticals and Chemical Co dd filed Critical Lek Pharmaceuticals and Chemical Co dd
Application granted granted Critical
Publication of DE69615017D1 publication Critical patent/DE69615017D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2072Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
DE69615017T 1995-05-19 1996-05-17 Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung Expired - Lifetime DE69615017D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SI9500173A SI9500173B (sl) 1995-05-19 1995-05-19 Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo
PCT/SI1996/000012 WO1996036318A2 (en) 1995-05-19 1996-05-17 Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application

Publications (1)

Publication Number Publication Date
DE69615017D1 true DE69615017D1 (de) 2001-10-11

Family

ID=20431627

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69615017T Expired - Lifetime DE69615017D1 (de) 1995-05-19 1996-05-17 Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung

Country Status (15)

Country Link
US (1) US6042847A (de)
EP (1) EP0827397B1 (de)
JP (1) JPH11505542A (de)
AT (1) ATE205081T1 (de)
AU (1) AU698360B2 (de)
CZ (1) CZ288598B6 (de)
DE (1) DE69615017D1 (de)
HU (1) HUP9901457A3 (de)
PL (1) PL184183B1 (de)
RO (1) RO117148B1 (de)
RU (1) RU2161956C2 (de)
SI (1) SI9500173B (de)
SK (1) SK282000B6 (de)
UA (1) UA42062C2 (de)
WO (1) WO1996036318A2 (de)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
IT1284604B1 (it) * 1996-09-27 1998-05-21 Roberto Valducci Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva
FR2758459B1 (fr) * 1997-01-17 1999-05-07 Pharma Pass Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
FR2783421B1 (fr) * 1998-09-17 2000-11-24 Cll Pharma Procede de preparation de nouvelles formulations galeniques du fenofibrate, formulations galeniques obtenues par ledit procede et leurs applications
US7939105B2 (en) * 1998-11-20 2011-05-10 Jagotec Ag Process for preparing a rapidly dispersing solid drug dosage form
US6814977B1 (en) 1998-12-18 2004-11-09 Abbott Laboratories Formulations comprising lipid-regulating agents
US6838091B2 (en) 1998-12-18 2005-01-04 Abbott Laboratories Formulations comprising lipid-regulating agents
US7014864B1 (en) 1998-12-18 2006-03-21 Abbott Laboratories Formulations comprising lipid-regulating agents
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6719999B2 (en) 1999-03-31 2004-04-13 Abbott Laboratories Formulations comprising lipid-regulating agents
US6465011B2 (en) * 1999-05-29 2002-10-15 Abbott Laboratories Formulations comprising lipid-regulating agents
US8895064B2 (en) 1999-06-14 2014-11-25 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
JP4790950B2 (ja) 1999-06-14 2011-10-12 コスモ・テクノロジーズ・リミテッド 制御放出および味感遮蔽経口医薬組成物
US20030236236A1 (en) * 1999-06-30 2003-12-25 Feng-Jing Chen Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
US6982281B1 (en) 2000-11-17 2006-01-03 Lipocine Inc Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
GB9920558D0 (en) * 1999-08-31 1999-11-03 Bradford Particle Design Ltd Methods for particle formation and their products
EA200200240A1 (ru) 1999-10-11 2002-10-31 Пфайзер Инк. 5-(2-ЗАМЕЩЕННЫЕ-5-ГЕТЕРОЦИКЛИЛСУЛЬФОНИЛПИРИД-3-ИЛ)-ДИГИДРОПИРАЗОЛО[4,3-d]ПИРИМИДИН-7-ОНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ФОСФОДИЭСТЕРАЗЫ
DE60028754T2 (de) * 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8586094B2 (en) * 2000-09-20 2013-11-19 Jagotec Ag Coated tablets
CA2423336C (en) * 2000-09-20 2011-03-08 Rtp Pharma Inc. Stabilised fibrate microparticles
FR2819720B1 (fr) * 2001-01-22 2004-03-12 Fournier Lab Sa Nouveaux comprimes de fenofibrate
US20080058424A1 (en) * 2002-05-23 2008-03-06 Cephalon, Inc. Novel pharmaceutical formulations of modafinil
EP1269994A3 (de) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmazeutische Zusammensetzungen die ein Arzneimittel und die Konzentration verbesserende Polymere enthalten
US20030114497A1 (en) * 2001-07-31 2003-06-19 Laman Alani Pharmaceutical compositions of amlodipine and atorvastatin
EP1474144B1 (de) 2002-02-01 2008-08-06 Pfizer Products Inc. Pharmazeutische darreichungsform mit gesteuerter freigabe eines cholesterylester-transferproteininhibitors
US7229644B2 (en) * 2002-05-23 2007-06-12 Cephalon, Inc. Pharmaceutical formulations of modafinil
US7445796B2 (en) * 2002-08-19 2008-11-04 L. Perrigo Company Pharmaceutically active particles of a monomodal particle size distribution and method
US20040116532A1 (en) 2002-09-13 2004-06-17 Craig Heacock Pharmaceutical formulations of modafinil
EP1400835B1 (de) * 2002-09-17 2011-11-16 Nippon Telegraph And Telephone Corporation Optischer Halbleitermodulator und Laser mit einem solchen Modulator
EP1572190B1 (de) * 2002-12-17 2007-04-18 Abbott GmbH & Co. KG Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
US20080051411A1 (en) * 2002-12-17 2008-02-28 Cink Russell D Salts of Fenofibric Acid and Pharmaceutical Formulations Thereof
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US20060003002A1 (en) * 2003-11-03 2006-01-05 Lipocine, Inc. Pharmaceutical compositions with synchronized solubilizer release
KR100598326B1 (ko) 2004-04-10 2006-07-10 한미약품 주식회사 HMG-CoA 환원효소 억제제의 경구투여용 서방형 제제및 이의 제조방법
WO2006033435A1 (ja) * 2004-09-24 2006-03-30 Hi-Lex Corporation 生体硬組織または軟組織誘導性スカフォールド材料
EP1830822A1 (de) * 2004-12-24 2007-09-12 LEK Pharmaceuticals D.D. Stabile pharmazeutische zusammensetzung mit einer wirksubstanz in form einer festen lösung
EP1785133A1 (de) 2005-11-10 2007-05-16 Laboratoires Fournier S.A. Verwendung von Fenofibrate oder dessen Derivaten zur Prävention von diabetischer retinopathie
CA2640460C (en) * 2006-01-27 2015-05-26 Eurand, Inc Drug delivery systems comprising weakly basic selective serotonin 5-ht3 blocking agent and organic acids
EP1837020A1 (de) 2006-03-24 2007-09-26 Bioalliance Pharma Bioadhäsive Schleimhautträger zur langsamen Verabreichung von aktiven Substanzen
US9254266B2 (en) * 2007-03-21 2016-02-09 Wisconsin Alumni Research Foundation Inhibiting surface enhanced crystallization of amorphous pharmaceuticals with ultrathin coatings
DE102007048705A1 (de) * 2007-10-11 2009-04-16 Bayer Healthcare Ag Amorphe Formulierung
WO2009085766A2 (en) * 2007-12-19 2009-07-09 Mutual Pharmaceutical Company, Inc. Fenofibric acid amorphous dispersion; method of making; and method of use thereof
US20090187040A1 (en) * 2008-01-18 2009-07-23 Tong Sun Fenofibric acid polymorphs; methods of making; and methods of use thereof
EP2257220B1 (de) * 2008-03-13 2017-06-14 Liebel-Flarsheim Company LLC Fussbetätigte multifunktionssteuerung für bildgebungssystem
US20100159001A1 (en) * 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
US20100160363A1 (en) * 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US11304960B2 (en) 2009-01-08 2022-04-19 Chandrashekar Giliyar Steroidal compositions
PT2455376E (pt) * 2009-06-11 2015-03-04 Abbvie Bahamas Ltd Compostos heterocíclicos como inibidores do vírus da hepatite c (hcv)
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
JP5775071B2 (ja) 2009-06-16 2015-09-09 ファイザー・インク アピキサバンの製剤形
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US20180153904A1 (en) 2010-11-30 2018-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US9034858B2 (en) 2010-11-30 2015-05-19 Lipocine Inc. High-strength testosterone undecanoate compositions
US9358241B2 (en) 2010-11-30 2016-06-07 Lipocine Inc. High-strength testosterone undecanoate compositions
US20120148675A1 (en) 2010-12-10 2012-06-14 Basawaraj Chickmath Testosterone undecanoate compositions
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US10154964B2 (en) 2011-09-07 2018-12-18 Cosmo Technologies Limited Controlled release and taste masking oral pharmaceutical composition
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015038376A1 (en) * 2013-09-11 2015-03-19 3M Innovative Properties Company Coating compositions, dental structures thereof and methods for generating contrast
EP3089757A1 (de) 2014-01-03 2016-11-09 AbbVie Inc. Feste antivirale darreichungsformen
WO2016033549A2 (en) 2014-08-28 2016-03-03 Lipocine Inc. (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
US9498485B2 (en) 2014-08-28 2016-11-22 Lipocine Inc. Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters
TWI525103B (zh) 2014-12-29 2016-03-11 財團法人工業技術研究院 改質纖維素與及應用其之複合材料
US20180147215A1 (en) 2016-11-28 2018-05-31 Lipocine Inc. Oral testosterone undecanoate therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1579818A (en) * 1977-06-07 1980-11-26 Yamanouchi Pharma Co Ltd Nifedipine-containing solid preparation composition
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US5264446A (en) * 1980-09-09 1993-11-23 Bayer Aktiengesellschaft Solid medicament formulations containing nifedipine, and processes for their preparation
US4327725A (en) * 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
US4612008A (en) * 1983-05-11 1986-09-16 Alza Corporation Osmotic device with dual thermodynamic activity
US4783337A (en) * 1983-05-11 1988-11-08 Alza Corporation Osmotic system comprising plurality of members for dispensing drug
US4765989A (en) * 1983-05-11 1988-08-23 Alza Corporation Osmotic device for administering certain drugs
WO1987000044A1 (en) * 1985-07-02 1987-01-15 The Upjohn Company Therapeutic formulations with bimodal release characteristics
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4786503A (en) * 1987-04-06 1988-11-22 Alza Corporation Dosage form comprising parallel lamine
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette
US4792452A (en) * 1987-07-28 1988-12-20 E. R. Squibb & Sons, Inc. Controlled release formulation
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
BE1004243A3 (fr) * 1990-05-17 1992-10-20 Europharmaceuticals Sa Compositions pharmaceutiques du type a liberation prolongee destinees a l'administration par voie orale et leur procede de preparation.
DE4226753A1 (de) * 1992-08-13 1994-02-17 Basf Ag Wirkstoffe enthaltende Zubereitungen in Form fester Teilchen

Also Published As

Publication number Publication date
EP0827397B1 (de) 2001-09-05
HUP9901457A3 (en) 2000-06-28
WO1996036318A2 (en) 1996-11-21
SI9500173B (sl) 2002-02-28
SK282000B6 (sk) 2001-10-08
RO117148B1 (ro) 2001-11-30
WO1996036318A3 (en) 1997-01-16
ATE205081T1 (de) 2001-09-15
AU5710396A (en) 1996-11-29
PL184183B1 (pl) 2002-09-30
SK153497A3 (en) 1998-04-08
CZ365597A3 (cs) 1998-04-15
PL323487A1 (en) 1998-03-30
SI9500173A (en) 1996-12-31
EP0827397A2 (de) 1998-03-11
AU698360B2 (en) 1998-10-29
UA42062C2 (uk) 2001-10-15
HUP9901457A2 (hu) 1999-08-30
CZ288598B6 (cs) 2001-07-11
RU2161956C2 (ru) 2001-01-20
US6042847A (en) 2000-03-28
JPH11505542A (ja) 1999-05-21

Similar Documents

Publication Publication Date Title
DE69615017D1 (de) Dreiphasen-pharmazeutische form mit konstanter und gesteuerter freisetzung eines amorphen wirkstoffs zur einmaligen täglichen anwendung
US4927639A (en) Modified release gemfibrozil composition
BR0105102A (pt) Medicamento de multiplas camadas para a liberação no cólon
CA2027053A1 (en) Estrogen-Containing Active Substance Plaster
ATE222505T1 (de) Flüssige polymerzusammensetzung und verfahren zu ihrer verwendung
PT93384A (pt) Processo para a preparacao de um material de revestimento de controlo da libertacao de droga para formulacoes de accao prolongada contendo copolimeros de (met)acrilato
CN101437500B (zh) 用于透皮吸收的组合物和包含由其形成的聚合基质的制剂
JPH0827003A (ja) 経皮吸収製剤
EE200100433A (et) Klaritromütsiini, rasv- ja hüdrofiilse komponendisegu sisaldav farmatseutiline preparaat, meetod selle valmistamiseks ning kasutamine
AU4339797A (en) Viral inhibition by long-chain alcohols, alkanes, fatty acids and amides
BRPI0011404B8 (pt) microgrânulos de sulfato de morfina de liberação prolongada, processo de preparação dos mesmos e composição farmacêutica.
RU2003107072A (ru) Применение гормональной композиции, содержащей сочетание эстрогена и прогестагена
JPH0892080A (ja) 経皮吸収用製剤
MXPA04006256A (es) Formulaciones transdermicas adhesivas de diclofenac sodico.
DK0850049T3 (da) Præparat til pH-afhængig reguleret afgivelse af aktive bestanddele og fremgangsmåder til fremstilling heraf
JPS6117510A (ja) 口腔粘膜適用徐放性ニフエジピン製剤
CA2259584A1 (en) Plasters containing isosorbide dinitrate
JP2004131495A (ja) 非ステロイド系抗炎症剤の局所送達用医薬組成物
JPH11199521A (ja) 皮膚外用剤
JPH05306225A (ja) 持続性製剤
RU2001122815A (ru) Фармацевтическая смесь, содержащая сочетание профена и других активных соединений
JPS62240613A (ja) 貼付剤
JP3994048B2 (ja) レプリカ作成用の組成物キット
ES2172172T3 (es) Composiciones farmaceuticas solidas para la administracion por via oral que permiten la liberacion modulada de nicorandil y su procedimiento de preparacion.
JPS5785318A (en) Hydrophilic medical material

Legal Events

Date Code Title Description
8332 No legal effect for de